Global Patent Index - EP 3033150 A4

EP 3033150 A4 20170628 - ADMINISTRATION OF KARENITECIN FOR THE TREATMENT OF ADVANCED OVARIAN CANCER, INCLUDING CHEMOTHERAPY-RESISTANT AND/OR THE MUCINOUS ADENOCARCINOMA SUB-TYPES

Title (en)

ADMINISTRATION OF KARENITECIN FOR THE TREATMENT OF ADVANCED OVARIAN CANCER, INCLUDING CHEMOTHERAPY-RESISTANT AND/OR THE MUCINOUS ADENOCARCINOMA SUB-TYPES

Title (de)

VERABREICHUNG VON KARENITECIN ZUR BEHANDLUNG VON FORTGESCHRITTENEM EIERSTOCKKREBS, MIT CHEMOTHERAPIERESISTENTEN SUBTYPEN UND/ODER SUBTYPEN DES MUZINÖSEN ADENOKARZINOMS

Title (fr)

ADMINISTRATION DE KARÉNITÉCINE POUR TRAITER UN CANCER AVANCÉ DE L'OVAIRE, Y COMPRIS DES SOUS-TYPES D'ADÉNOCARCINOMES CHIMIO-RÉSISTANTS ET/OU MUCINEUX

Publication

EP 3033150 A4 20170628 (EN)

Application

EP 14836702 A 20140810

Priority

  • US 201361865360 P 20130813
  • US 2014050463 W 20140810

Abstract (en)

[origin: WO2015023551A1] The present invention discloses and claims methods and compositions for the treatment of platinum and/or taxane cancer treating agent-resistanf-refractory sub-populations and/or the mucinous adenocarcinoma sub-type of ovarian cancer subjects with the silicon-containing highly lipophilic camptothecin derivative (HLCD), Karenitecin (also known as BNP1350; cositecan; 7-[(2'-trimethylsilyl) ethyl]-20(S) camptothecin). The administration of Karenitecin by intravenous (i.v.) and/or oral methodologies are also disclosed and claimed.

IPC 8 full level

A61K 31/4745 (2006.01); A61K 31/185 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)

CPC (source: EP)

A61K 31/185 (2013.01); A61K 31/4745 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2017.12)

C-Set (source: EP)

  1. A61K 31/4745 + A61K 2300/00
  2. A61K 31/185 + A61K 2300/00

Citation (search report)

  • [X] WO 2005113018 A2 20051201 - WELLSTAT BIOLOGICS CORP [US], et al
  • [X] NAUMANN R WENDEL ET AL: "Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer", DRUGS, ADIS INTERNATIONAL LTD, NZ, vol. 71, no. 11, 1 January 2011 (2011-01-01), pages 1397 - 1412, XP009165133, ISSN: 0012-6667, DOI: 10.2165/11591720-000000000-00000
  • [X] MUNSTER PAMELA N ET AL: "Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 20, no. 11, November 2011 (2011-11-01), pages 1565 - 1574, XP002766330
  • [A] ANNEMARIE H. VAN HATTUM ET AL: "New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer", INTERNATIONAL JOURNAL OF CANCER, vol. 88, no. 2, 15 October 2000 (2000-10-15), pages 260 - 266, XP055007980, ISSN: 0020-7136, DOI: 10.1002/1097-0215(20001015)88:2<260::AID-IJC18>3.0.CO;2-Q
  • See references of WO 2015023551A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2015023551 A1 20150219; EP 3033150 A1 20160622; EP 3033150 A4 20170628; WO 2015023552 A1 20150219; WO 2015023553 A2 20150219; WO 2015023553 A3 20150423

DOCDB simple family (application)

US 2014050463 W 20140810; EP 14836702 A 20140810; US 2014050464 W 20140810; US 2014050465 W 20140810